Business Context and Reporting Period
This Form 8-K Current Report is filed by Frequency Therapeutics, Inc. (not Korro Bio, Inc., as indicated in the metadata) on March 25, 2022. The report addresses a significant executive departure effective March 31, 2022.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation and separation terms.
- Severance Base Salary: 12 months of base salary continuation.
- Bonus Payment: $189,000 (100% of 2022 bonus opportunity).
- Relocation Expenses: $20,000.
- Benefits: Company contribution to COBRA premiums during the severance period.
Material Changes
The primary material change is the departure of Peter P. Pfreundschuh as Chief Financial Officer. The filing explicitly states that the departure did not result from any disagreement with the Company regarding operations, policies, or practices.
Outlook, Risks, and Contingencies
The financial obligations outlined in the Separation Agreement are contingent upon Mr. Pfreundschuh not revoking the agreement within seven days of signing and complying with its terms, including granting a general release of claims. No specific business outlook or new risk factors were disclosed in this report.
Investor Verification Checklist
- Verify the appointment of an interim or permanent replacement for the CFO role.
- Review the full Separation Agreement (Exhibit 10.1) for additional restrictive covenants or clawback provisions.
- Confirm the impact of the $209,000 in immediate cash payments ($189,000 bonus + $20,000 relocation) on the company's current cash position.
- Monitor subsequent filings for any changes in financial reporting timelines or internal controls resulting from the CFO transition.